Literature DB >> 27382942

Achieving WHO recommendations for Hepatitis C Virus Elimination in Belgium.

S Bourgeois, S Blach, C Blach, W Laleman, C Matheï, J P Mulkay, H Ravazi, G Robaeys, P Stärkel, P Van Damme, H Van Vlierberghe, D Vandijck, C Vandijck.   

Abstract

BACKGROUD: The World Health Organization (WHO) released updated guidelines for the screening, care and treatment of patients with chronic hepatitis C virus (HCV) infection.
METHODS: A previously described HCV disease burden model was used to develop a "WHO scenario" to achieve the WHO recommendations of a 90% reduction in incidence and 65% reduction in liver-related deaths. After determining the steps necessary to achieve this goal, the impact of realistic constraints was modeled.
RESULTS: In 2015, there were 66.200 viremic infections, with 43% diagnosed and 1.350 treated. In order to reduce new infections, treatment must be extended to ≥ F0 patients, including people who inject drugs and other individuals at risk of transmitting HCV. -Additionally, diagnosis and treatment of 3.030 and 4.060 patients, respectively, would be required. The largest attenuation of the WHO scenario would occur if no new cases were diagnosed after 2018 (300% more viremic infections by 2030). Limiting treatment to ≥ F2 patients or treating fewer patients (3.000) would result in 220% or 140% more viremic cases, respectively, compared with the WHO scenario.
CONCLUSION: Achieving the WHO guidelines in Belgium requires a coordinated effort to scale up treatment and prevention efforts and to allow treatment access to patients of all fibrosis stages. A scale-up of treatment, however, requires patients to be both diagnosed and linked to care, suggesting a need for increased awareness and expanded screening efforts. Finally, prevention of new HCV infections requires a comprehensive understanding of the population at risk of transmitting HCV. © Acta Gastro-Enterologica Belgica.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27382942

Source DB:  PubMed          Journal:  Acta Gastroenterol Belg        ISSN: 1784-3227            Impact factor:   1.316


  6 in total

1.  HCV elimination - lessons learned from a small Eurasian country, Georgia.

Authors:  Muazzam Nasrullah; David Sergeenko; Amiran Gamkrelidze; Francisco Averhoff
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-07-26       Impact factor: 46.802

2.  Ten years countdown to hepatitis C elimination in Belgium: a mathematical modeling approach.

Authors:  Erwin Ho; Thomas Vanwolleghem; Dana Busschots; Sarah Blach; Frederik Nevens; Homie Razavi; Brieuc Van Damme; Geert Robaeys
Journal:  BMC Infect Dis       Date:  2022-04-22       Impact factor: 3.667

3.  The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up.

Authors:  Robert Hecht; Lindsey Hiebert; Wendy C Spearman; Mark W Sonderup; Teresa Guthrie; Timothy B Hallett; Shevanthi Nayagam; Homie Razavi; Shan Soe-Lin; Kgomotso Vilakazi-Nhlapo; Yogan Pillay; Stephen Resch
Journal:  Health Policy Plan       Date:  2018-05-01       Impact factor: 3.344

Review 4.  Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence.

Authors:  Lauren E Cipriano; Jeremy D Goldhaber-Fiebert
Journal:  MDM Policy Pract       Date:  2018-05-24

5.  Assessing testing rates for viral hepatitis B and C by general practitioners in Flanders, Belgium: a registry-based study.

Authors:  Rob Bielen; Özgür M Koc; Dana Busschots; Geert Robaeys; Bert Aertgeerts; Bert Vaes; Pavlos Mamouris; Catharina Mathei; Geert Goderis; Frederik Nevens
Journal:  BMJ Open       Date:  2019-05-09       Impact factor: 2.692

6.  Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030.

Authors:  Benedikt Schaefer; André Viveiros; Ramona Al-Zoairy; Sarah Blach; Samantha Brandon; Homie Razavi; Livia Dorn; Armin Finkenstedt; Maria Effenberger; Ivo Graziadei; Mario Sarcletti; Herbert Tilg; Heinz Zoller
Journal:  PLoS One       Date:  2018-07-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.